GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
Subscribe for instant access to all Lawyerly content.
